PE20070762A1 - Forma de dosificacion osmotica con aspectos de liberacion controlada y de liberacion rapida - Google Patents
Forma de dosificacion osmotica con aspectos de liberacion controlada y de liberacion rapidaInfo
- Publication number
- PE20070762A1 PE20070762A1 PE2006001214A PE2006001214A PE20070762A1 PE 20070762 A1 PE20070762 A1 PE 20070762A1 PE 2006001214 A PE2006001214 A PE 2006001214A PE 2006001214 A PE2006001214 A PE 2006001214A PE 20070762 A1 PE20070762 A1 PE 20070762A1
- Authority
- PE
- Peru
- Prior art keywords
- layer
- semi
- release
- permeable membrane
- drug
- Prior art date
Links
- 238000013270 controlled release Methods 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 title abstract 2
- 230000003204 osmotic effect Effects 0.000 title abstract 2
- 239000012528 membrane Substances 0.000 abstract 7
- 229940079593 drug Drugs 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract 2
- 230000004888 barrier function Effects 0.000 abstract 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229960002274 atenolol Drugs 0.000 abstract 1
- 229910000389 calcium phosphate Inorganic materials 0.000 abstract 1
- 239000001506 calcium phosphate Substances 0.000 abstract 1
- 235000011010 calcium phosphates Nutrition 0.000 abstract 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 abstract 1
- 229940106164 cephalexin Drugs 0.000 abstract 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 abstract 1
- 229960005156 digoxin Drugs 0.000 abstract 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 abstract 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 abstract 1
- 229960003520 diphenidol Drugs 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 229960003276 erythromycin Drugs 0.000 abstract 1
- 235000003891 ferrous sulphate Nutrition 0.000 abstract 1
- 239000011790 ferrous sulphate Substances 0.000 abstract 1
- 239000002357 osmotic agent Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 abstract 1
- 229960000620 ranitidine Drugs 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UNA FORMA DE LIBERACION OSMOTICA QUE COMPRENDE: a) UNA MEMBRANA SEMI-PERMEABLE, b) UN PRIMER Y UN SEGUNDO ORIFICIO EN LA MEMBRANA SEMI-PERMEABLE UBICADO EN EXTREMOS OPUESTOS DE DICHA MEMBRANA, c) UNA CAPA DE UN FARMACO DE LIBERACION CONTROLADA UBICADA ADYACENTE AL PRIMER ORIFICIO Y DENTRO DE LA MEMBRANA SEMIPERMEABLE, d) UNA CAPA DE UN FARMACO DE LIBERACION RAPIDA UBICADA ADYACENTE AL SEGUNDO ORIFICIO Y DENTRO DE LA MEMBRANA SEMI-PERMEABLE, e) UNA CAPA DE EMPUJE UBICADA DENTRO DE LA MEMBRANA SEMI-PERMEABLE Y ENTRE LA CAPA DE FARMACO DE LIBERACION CONTROLADA Y LA CAPA DE FARMACO DE LIBERACION RAPIDA Y f) UNA CAPA BARRERA UBICADA DE MODO DESLIZABLE ENTRE LA CAPA DE EMPUJE Y LA CAPA DE FARMACO DE LIBERACION RAPIDA. DICHA FORMA DE DOSIFICACION PUEDE CONTENER UNO O MAS ORIFICIOS ADICIONALES ADYACENTES AL PRIMER O SEGUNDO ORIFICIO; LA CAPA DE LIBERACION CONTROLADA COMPRENDE UN AGENTE OSMOTICO; LA CAPA DE LIBERACION RAPIDA COMPRENDE UN DESINTEGRANTE TAL COMO CROSCARMELOSA SODICA O POLIVINILPIRROLIDONA ENTRECRUZADA; LA CAPA BARRERA COMPRENDE ETILCELULOSA, FOSFATO DE CALCIO, ENTRE OTROS; Y EL FARMACO PUEDE SER EDISILATO DE PROCLOROPERZINA, SULFATO FERROSO, BROMURO DE ESCOPOLAMINA, DIFENIDOL, DIGOXINA, ERITROMICINA, RANITIDINA, ATENOLOL, CEFALEXINA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72447005P | 2005-10-07 | 2005-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070762A1 true PE20070762A1 (es) | 2007-08-11 |
Family
ID=37775283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001214A PE20070762A1 (es) | 2005-10-07 | 2006-10-05 | Forma de dosificacion osmotica con aspectos de liberacion controlada y de liberacion rapida |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070190137A1 (es) |
| AR (1) | AR055682A1 (es) |
| PE (1) | PE20070762A1 (es) |
| UY (1) | UY29845A1 (es) |
| WO (1) | WO2007044234A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| EP2161019A1 (en) | 2008-09-05 | 2010-03-10 | KRKA, D.D., Novo Mesto | Prolonged release multiparticulate pharmaceutical composition comprising paliperidone |
| WO2010089775A2 (en) * | 2009-02-05 | 2010-08-12 | Getz Pharma Research | Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent |
| WO2011018246A2 (en) | 2009-08-13 | 2011-02-17 | Synthon B.V. | Controlled release paliperidone composition |
| US20110052687A1 (en) * | 2009-08-26 | 2011-03-03 | Glenmark Generics Ltd | Extended release pharmaceutical composition of paliperidone |
| CN101711752B (zh) * | 2009-11-26 | 2011-09-21 | 中国科学院上海药物研究所 | 一种苯并异噁唑类衍生物的控释制剂及其制备方法 |
| US20120201886A1 (en) | 2010-07-30 | 2012-08-09 | Micro Labs Limited | Coated Extended Release Pharmaceutical Compositions Containing Paliperidone |
| US20130034605A1 (en) | 2011-08-01 | 2013-02-07 | Micro Labs Limited | Extended release pharmaceutical compositions containing paliperidone |
| WO2014102741A2 (en) * | 2012-12-28 | 2014-07-03 | University Of The Witwatersrand, Johannesburg | Pharmaceutical dosage form |
| GR1008842B (el) | 2015-08-06 | 2016-09-05 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου |
| WO2017174096A1 (en) | 2016-04-05 | 2017-10-12 | Pharmathen S.A. | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2799241A (en) * | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
| US3995631A (en) * | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4455143A (en) * | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
| US4519801A (en) * | 1982-07-12 | 1985-05-28 | Alza Corporation | Osmotic device with wall comprising cellulose ether and permeability enhancer |
| US4681583A (en) * | 1982-12-20 | 1987-07-21 | Alza Corporation | System for dispersing drug in biological environment |
| US4578075A (en) * | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
| US4814181A (en) * | 1987-09-03 | 1989-03-21 | Alza Corporation | Dosage form comprising fast agent delivery followed by slow agent delivery |
| US4915953A (en) * | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering acetaminophen or phenylpropanolamine |
| US5271946A (en) * | 1988-04-20 | 1993-12-21 | Asta Pharma Aktiengesellschaft | Controlled release azelastine-containing pharmaceutical compositions |
| US5019397A (en) * | 1988-04-21 | 1991-05-28 | Alza Corporation | Aqueous emulsion for pharmaceutical dosage form |
| US5045082A (en) * | 1990-01-10 | 1991-09-03 | Alza Corporation | Long-term delivery device including loading dose |
| US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| US5284662A (en) * | 1990-10-01 | 1994-02-08 | Ciba-Geigy Corp. | Oral osmotic system for slightly soluble active agents |
| US5227167A (en) * | 1991-06-11 | 1993-07-13 | Alza Corporation | Long-term delivery device including hydrophobic loading dose |
| US5240713A (en) * | 1991-09-27 | 1993-08-31 | Alza Corporation | Dual rate agent delivery device |
| US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| US6387403B1 (en) * | 1999-09-15 | 2002-05-14 | Alza Corporation | Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| US20020086054A1 (en) * | 2001-01-02 | 2002-07-04 | Jiajiu Shaw | Controlled release system that needs no drilling |
| EP1534238A1 (en) * | 2002-07-29 | 2005-06-01 | ALZA Corporation | Formulations and dosage forms for controlled delivery of topiramate |
| EP1701697A2 (en) * | 2003-09-02 | 2006-09-20 | ALZA Corporation | Novel drug compositions and dosage forms of topiramate |
| US20050287213A1 (en) * | 2004-06-28 | 2005-12-29 | Wong Patrick S | Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents |
-
2006
- 2006-09-26 WO PCT/US2006/037760 patent/WO2007044234A1/en not_active Ceased
- 2006-09-26 US US11/528,053 patent/US20070190137A1/en not_active Abandoned
- 2006-10-05 PE PE2006001214A patent/PE20070762A1/es not_active Application Discontinuation
- 2006-10-06 UY UY29845A patent/UY29845A1/es unknown
- 2006-10-06 AR ARP060104427A patent/AR055682A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR055682A1 (es) | 2007-08-29 |
| US20070190137A1 (en) | 2007-08-16 |
| WO2007044234A1 (en) | 2007-04-19 |
| UY29845A1 (es) | 2006-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070762A1 (es) | Forma de dosificacion osmotica con aspectos de liberacion controlada y de liberacion rapida | |
| NO20080350L (no) | Selvfyllende modulaer barriere | |
| CL2012002522A1 (es) | Composición farmacéutica que comprende un compuesto inhibidor de dpp iv con un grupo amino o una sal del mismo , un primer diluyente , un segundo diluyente ,un aglutinante , un disgregante y un lubricante, útil en el tratamiento de diabetes mellitus. | |
| CR20140539A (es) | Preparación que contiene por lo menos un fungicida conazólico | |
| CL2008000751A1 (es) | Compuestos derivados de cicloprop[d]indolo[2,1-a][2]benzacepina sustituidos con heterociclos; composicion farmaceutica; y uso en el tratamiento de infeccion por hepatitis c. | |
| BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
| NO20076109L (no) | Substituerte arylpyrazoler, og anvendelser som parasitticidale midler | |
| CL2007003552A1 (es) | Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular. | |
| DK1866324T3 (da) | Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer | |
| CL2007003686A1 (es) | Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral. | |
| PL1829139T3 (pl) | Organiczna/nieorganiczna kompozytowa mikroporowata membrana i wykonane w ten sposób urządzenie elektrochemiczne | |
| CL2007003718A1 (es) | Compuestos macrociclos, inhibidores selectivos del factor viia de coagulacion de serinaproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de un trastorno tromboembolico. | |
| CL2007002167A1 (es) | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. | |
| NI201200033A (es) | Inserto para suelas permeables al vapor e impermeables al agua. | |
| CL2008003309A1 (es) | Compuestos derivados de citosina (=4-amino-pirimidin-2-ona) sustituida, moduladores de quinasas de punto de control del ciclo celular; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento o la disminucion de la progresion del cancer. | |
| NO20082376L (no) | Farmasoytiske sammensetninger | |
| PL2679220T3 (pl) | Tabletka typu pompy osmotycznej o kontrolowanej porowatości i sposób jej wytwarzania | |
| CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
| MX2009013595A (es) | Chupon. | |
| CL2008000254A1 (es) | Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer. | |
| ECSP11011001A (es) | Composición farmacéutica sólida | |
| BRPI0611065A2 (pt) | agente desespumente, e, composição de cimento. | |
| BRPI0720314A2 (pt) | Composição, e, usos de uma composição e de um composto de triazol. | |
| ATE494802T1 (de) | Fluoreszierendes energiegetränk auf koffeinbasis | |
| CL2007002321A1 (es) | Procedimiento de oxidacion de carbohidratos que comprende proveer un carbohidrato, combinar el carbohidrato con un oxidante seleccionado del grupo hipoclorito, bromuros, haluros y oxihaluros activos y someter a luz ultravioleta en condiciones alcalin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |